Targeted α-therapy in non-prostate malignancies.

Area of Science:

• Oncology
• Radiochemistry
• Nuclear Medicine

Background:

• Advances in cancer biology and radiochemistry enable targeted alpha-therapy (TAT).
• The success of Radium-223 dichloride (²²³Ra) in prostate cancer highlights TAT's potential.
• Research is exploring new alpha-emitters and biological targets for broader cancer applications.

Purpose of the Study:

• To review preclinical and first-in-human studies of TAT in various malignancies.
• To highlight the expanding scope of TAT beyond prostate cancer.
• To discuss the future potential of TAT in precision cancer management.

Main Methods:

• Review of preclinical research.
• Analysis of first-in-human clinical trial data.
• Synthesis of current data on targeted alpha-emitters and their biological targets.

Main Results:

• TAT is being investigated for brain, breast, lung, gastrointestinal, pancreas, ovarian, and bladder cancers.
• Studies also include leukemia, melanoma, myeloma, and neuroendocrine tumors.
• Emerging data suggest TAT's safety and efficacy across diverse cancer types.

Conclusions:

• Targeted alpha-therapy is a rapidly developing field with broad applicability in oncology.
• Further research is needed to define and validate the role of TAT in various cancer treatments.
• TAT represents an innovative approach to precision cancer management.